Johnson & Johnson
JNJ
259.69
+5.90
+2.32%
Johnson & Johnson
US · JNJ
#25 by market cap
Listed 1970
259.69
+5.90
+2.32%
Live - 5344 symbols - heartbeat 255s ago
· 2026-10-20 09:50
Analyst consensus 18 analysts
Buy
Avg price target 289.71 +11.6%
Price target rangecurrent 259.69
Low260.00
Avg289.71
High320.00
Buy 78%
Hold 22%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-09 | UBS | -- | Buy | 320.00 |
| 2026-10-09 | BofA Securities | -- | Hold | 282.00 |
| 2026-10-07 | Morgan Stanley | -- | Buy | 294.00 |
| 2026-10-07 | Leerink Partners | -- | Buy | -- |
| 2026-10-06 | Guggenheim | -- | Buy | 287.00 |
| 2026-10-06 | RBC Capital | -- | Buy | 290.00 |
| 2026-10-05 | Citi | -- | Buy | 303.00 |
| 2026-10-02 | Wells Fargo | -- | Buy | 282.00 |
| 2026-09-29 | BofA Securities | -- | Hold | 278.00 |
| 2026-09-29 | J.P. Morgan | -- | Hold | 285.00 |
| 2026-09-28 | Scotiabank | -- | Buy | 305.00 |
| 2026-09-22 | Scotiabank | -- | Buy | 305.00 |
| 2026-09-21 | UBS | -- | Buy | 320.00 |
| 2026-09-21 | RBC Capital | -- | Buy | 287.00 |
| 2026-09-18 | Scotiabank | -- | Buy | 305.00 |
| 2026-09-16 | RBC Capital | -- | Buy | 287.00 |
| 2026-09-14 | TD Cowen | -- | Buy | 300.00 |
| 2026-09-11 | DBS | -- | Hold | 270.00 |
| 2026-09-10 | HSBC | -- | Buy | 320.00 |
| 2026-09-09 | RBC Capital | -- | Buy | 287.00 |
| 2026-09-03 | UBS | -- | Buy | 320.00 |
| 2026-09-02 | UBS | -- | Buy | 320.00 |
| 2026-08-25 | Scotiabank | -- | Buy | 305.00 |
| 2026-08-25 | Goldman Sachs | -- | Buy | 282.00 |
| 2026-08-13 | Citi | -- | Buy | 298.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Improving
2
■ Upgrades■ Downgrades
- 2 upgrades vs 0 downgrades among tracked analyst rating changes.
- Most recent: Leerink Partners moved from Hold to Buy on 2026-05-13.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-05-13 | Leerink Partners | Hold → Buy | 265.00 |
| 2026-01-28 | Morgan Stanley | Hold → Buy | 262.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-13 | -- | ±3.19% | -5.73% (beat) |
| 2026/Q2 | 2026-07-15 | -- | ±2.94% | -2.69% (in line) |
| 2026/Q1 | 2026-04-14 | -- | ±3.04% | +0.90% (in line) |
| 2025/Q4 | 2026-01-21 | -- | ±2.79% | -0.09% (in line) |
| 2025/Q3 | 2025-10-14 | -- | ±2.75% | -0.03% (in line) |
| 2025/Q2 | 2025-07-16 | -- | ±2.81% | +6.19% (beat) |
| 2025/Q1 | 2025-04-15 | -- | ±2.90% | -0.48% (in line) |
| 2024/Q4 | 2025-01-22 | -- | ±2.51% | -1.94% (in line) |
| 2024/Q3 | 2024-10-15 | -- | ±2.80% | +1.55% (in line) |
| 2024/Q2 | 2024-07-17 | -- | ±2.81% | +3.69% (beat) |
| 2024/Q1 | 2024-04-16 | -- | ±2.78% | -2.13% (in line) |
| 2023/Q4 | 2024-01-23 | -- | ±2.64% | -1.64% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-20 09:50:14 · For reference only, not investment advice and not tailored to your situation.
talc litigation headlines still spook this stock every few months but the pharma pipeline keeps quietly delivering. slow and steady, exactly how I like my healthcare names.